% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • raysfrom98 raysfrom98 Sep 19, 2012 9:09 PM Flag

    What other biotechs are you guys looking at these days?

    Your pick of Celldex was, and is, wise. You posted six months ago, and at that time CLDX was at $3.98 for a short time in late April but has been in a steady climb all year. This week Celldex broke into $6.00 convincingly. Lots of Catalyst through the end of this year, and according to the CEO, Celldex is speaking with several partner suitors. I Think we will see many more upgrades this year as the excitement surrounding CDX-011 continues to build.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • NLNK & SRPT !!!!!!!

      • 2 Replies to kblumb
      • NewLink Genetics may be the next big thing in Immunotherapy .Phase III trial with SPA in post surgical Pancreatic C , with two planned interim looks first expected early next year second mid next year. Phas II results outstanding presented at ASCO last June. 1 billion US market 100% owned! 4 analysts follow all buys do your own DD.

      • I really like GenSpera (GNSZ). About to kick off their first Phase II for G-202 with trial sites in US and UK. Also about to uplist from OTCBB to NASDAQ.

        Technology platform is a prodrug approach to attacking solid tumors. In theory, better than ADCs because the drug is activated extracellularly, so you get "bystander" effect -- more potent and doesn't require every cell in tumor microenvironment to express the target.

        G-202 targets enzyme PSMA, which is expressed in vasculature of new tumor growth, so G-202 collapses existing tumor vasculature. Think Avastin, only much much better -- seriously, G-202 has blockbuster potential.

        GenSpera technology was developed over decades at Johns Hopkins.

47.87+0.53(+1.12%)Jul 31 4:00 PMEDT